CompletedNot Applicable

PSMA-PET Imaging for Advanced ACC/SDC

Netherlands25 participantsStarted 2017-10-25

Plain-language summary

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * locally advanced, recurrent or metastatic ACC/SDC * Age ≥ 18 years old * Ability to provide written informed consent Exclusion Criteria: * Contra-indication for PET imaging * Pregnancy * Breast feeding * Severe claustrophobia * Impaired renal function: MDRD \<30 ml/min/1,73 m2 * Impaired liver function: AST and ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver metastases)

What they're measuring

uptake of 68Ga-PSMA in ACC and SDC

Timeframe: 0 days

Trial details

NCT IDNCT03319641

SponsorRadboud University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-05-14

View on ClinicalTrials.gov More Salivary Gland Cancer trials